211 related articles for article (PubMed ID: 32844403)
1. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
[TBL] [Abstract][Full Text] [Related]
2. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
[TBL] [Abstract][Full Text] [Related]
3. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
Yousaf A; Tjien-Fooh FJ; Rentroia-Pacheco B; Quattrocchi E; Kobic A; Tempel D; Kolodney M; Meves A
Int J Dermatol; 2021 Jul; 60(7):851-856. PubMed ID: 33914348
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
[TBL] [Abstract][Full Text] [Related]
5. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
[TBL] [Abstract][Full Text] [Related]
6. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
Marchetti MA; Dusza SW; Bartlett EK
JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
[TBL] [Abstract][Full Text] [Related]
7. Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.
Whitman ED; Koshenkov VP; Gastman BR; Lewis D; Hsueh EC; Pak H; Trezona TP; Davidson RS; McPhee M; Guenther JM; Toomey P; Smith FO; Beitsch PD; Lewis JM; Ward A; Young SE; Shah PK; Quick AP; Martin BJ; Zolochevska O; Covington KR; Monzon FA; Goldberg MS; Cook RW; Fleming MD; Hyams DM; Vetto JT
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568719
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D
J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297
[TBL] [Abstract][Full Text] [Related]
9. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
Scott AM; Dale PS; Conforti A; Gibbs JN
Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
[TBL] [Abstract][Full Text] [Related]
10. Cervical sentinel lymph node biopsy for melanomas of the head and neck and upper thorax.
Wagner JD; Park HM; Coleman JJ; Love C; Hayes JT
Arch Otolaryngol Head Neck Surg; 2000 Mar; 126(3):313-21. PubMed ID: 10722003
[TBL] [Abstract][Full Text] [Related]
11. The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients.
Tassavor M; Martin BJ; Glazer AM
Anticancer Res; 2023 Oct; 43(10):4511-4516. PubMed ID: 37772588
[TBL] [Abstract][Full Text] [Related]
12. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
[TBL] [Abstract][Full Text] [Related]
13. Melanoma nodal management in Ontario the year after the 2012 American Society of Clinical Oncology and Society of Surgical Oncology guideline.
Latosinsky S; Allen B; Shariff SZ
Curr Oncol; 2019 Oct; 26(5):330-337. PubMed ID: 31708651
[TBL] [Abstract][Full Text] [Related]
14. CP-GEP (Merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?
Quattrocchi E; Meves ES; Meves A
Ital J Dermatol Venerol; 2023 Aug; 158(4):292-301. PubMed ID: 37539500
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
[TBL] [Abstract][Full Text] [Related]
16. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
17. Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies.
Sadurní MB; Meves A
Mod Pathol; 2022 Nov; 35(11):1509-1514. PubMed ID: 35654998
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.
Yamamoto M; Fisher KJ; Wong JY; Koscso JM; Konstantinovic MA; Govsyeyev N; Messina JL; Sarnaik AA; Cruse CW; Gonzalez RJ; Sondak VK; Zager JS
Cancer; 2015 May; 121(10):1628-36. PubMed ID: 25677366
[TBL] [Abstract][Full Text] [Related]
19. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.
Mulder EEAP; Johansson I; Grünhagen DJ; Tempel D; Rentroia-Pacheco B; Dwarkasing JT; Verver D; Mooyaart AL; van der Veldt AAM; Wakkee M; Nijsten TEC; Verhoef C; Mattsson J; Ny L; Hollestein LM; Olofsson Bagge R
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740520
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]